Video

Next steps for burst wave lithotripsy in kidney stones

Author(s):

Urology Times staff

“The take-home message is that there is a new form of lithotripsy,” says Jonathan D. Harper, MD.

In this video, Jonathan D. Harper, MD, discusses the next steps and the take-home message from the Journal of Urology study, “Fragmentation of Stones by Burst Wave Lithotripsy in the First 19 Humans,” for which he served as a study author. Harper is an associate professor of urology and adjunct associate professor of surgery at the University of Washington School of Medicine in Seattle.

Related Videos
Wayne Kuang, MD, answers a question during a Zoom video interview
Raveen Syan, MD, FPMRS, answers a question during a Zoom video interview
Mohamad Baker Berjaoui, MD, answers a question during a Zoom video interview
Related Content
FDA greenlights phase 1/2 trial of gene editing therapy for primary hyperoxaluria 1
December 19th 2024

FDA greenlights phase 1/2 trial of gene editing therapy for primary hyperoxaluria 1

Hannah Clarke
The redePHine trial is expected to launch in the first half of 2025.
Why kidney stones will become more prevalent over time
February 17th 2022

Why kidney stones will become more prevalent over time

Urology Times staff
“The prevalence of kidney stones has increased over 80% over the last 30 years, and the epidemiology has changed such that it's beginning at a younger age now,” says Gregory Tasian, MD, MSc, MSCE.
FDA grants rare pediatric disease designation to YOLT-203 for primary hyperoxaluria type 1
September 4th 2024

FDA grants rare pediatric disease designation to YOLT-203 for primary hyperoxaluria type 1

Hannah Clarke
YOLT-203 is currently being assessed in the early phase 1 YOLT-203-101 trial.
Dr. Krambeck investigates efficacy of Trilogy and ShockPulse-SE lithotripters
September 9th 2021

Dr. Krambeck investigates efficacy of Trilogy and ShockPulse-SE lithotripters

Urology Times staff
“You have tradeoffs with every device that you use,” says Amy E. Krambeck, MD.
Increasing thiazide doses linked to fewer kidney stone events
August 27th 2024

Increasing thiazide doses linked to fewer kidney stone events

Hannah Clarke
“What this means for patients is that thiazides remain an important option in the toolkit for preventing kidney stone recurrence,” says Ryan S. Hsi, MD, FACS.
Trial launches of gene editing therapy for primary hyperoxaluria type 1
August 24th 2024

Trial launches of gene editing therapy for primary hyperoxaluria type 1

Hannah Clarke
In total, the trial plans to enroll 7 patients with PH1 through a single center in China.
© 2024 MJH Life Sciences

All rights reserved.